Aurisco Pharmaceutical Co.,Ltd. (605116.SS) has a MoatMap StockRank of 51/100 based on Quality (69/100), Value (37/100), and Momentum (32/100) factor scores. The current signal is HOLD. Aurisco Pharmaceutical is successfully transitioning from a generic API manufacturer to a high-value CDMO specializing in peptides (GLP-1s) and oligonucleotides. With global shortages of GLP-1 manufacturing capacity and the US Biosecure Act driving business away from larger Chinese competitors, Aurisco is well-positioned to capture significant market share as a validated, high-quality alternative CDMO with strong pricing power.
Aurisco Pharmaceutical is a high-tech pharmaceutical company specializing in the research, development, and manufacture of complex Active Pharmaceutical Ingredients (APIs) and formulations, with a focus on steroids, peptides, and oligonucleotides. The company operates as a key CDMO/API partner for global pharmaceutical majors, utilizing advanced synthetic biology and continuous flow chemistry. Its competitive moat is reinforced by stringent global regulatory approvals (FDA, EMA) and high-barrier technical capabilities.
| Price | $2.70 |
| Market Cap | $1.2B |
| P/E (TTM) | 19.72 |
| P/E (Forward) | 14.91 |
| Price/Book | 2.81 |
| Return on Equity | 15.3% |
| Return on Invested Capital | 14.9% |
| Debt/Equity | 35.66 |
| Gross Margin | 57.2% |
| Operating Margin | 23.5% |
| Revenue Growth | -3.2% |
| Dividend Yield | 1.5% |
| Free Cash Flow | $1M |
Aurisco Pharmaceutical Co.,Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).